Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice

Neoplasia

Volumn 9, Issue 5, 2007, Pages 392-400

  Seierstad, Therese ^a,c   Folkvord, Sigurd ^a   Røe, Kathrine ^a   Flatmark, Kjersti ^a   Skretting, Arne ^a   Olsen, Dag Rune ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

Apparent diffusion coefficient; Capecitabine; HT29; Oxaliplatin; Prediction of therapy response

Indexed keywords

CAPECITABINE; GLUCOSE; OXALIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EARLY DIAGNOSIS; FEMALE; MOUSE; NONHUMAN; NUDE MOUSE; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

EID: 34249007448     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07154     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, and Pisani P (2001). Estimating the world cancer burden. Globocan. Int J Cancer 94, 153-156.
2. Heald RJ, Husband EM, and Ryall RDH (1982). The mesorectum in rectum cancer surgery: the clue to pelvic recurrence. Br J Surg 69, 613-616.
3. Glimelius B, Grönberg H, Järhult J, Wallgren A, and Cavallin-Ståhl E (2003). A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 42, 476-492.
4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351, 1731-1740.
5. Kim HK, Jessup JM, Beard CJ, Bornstein B, Cady B, Stone MD, Bleday R, Bothe A Jr, Steele G Jr, and Busse PM (1997). Locally advanced rectal carcinoma: pelvic control and morbidity following preoperative radiation therapy, resection, and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 38, 777-783.
6. Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, et al. (2001). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345, 638-646.
7. 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73, 61-64.
8. Moffat BA, Hall DE, Stojanovska J, McConville PJ, Moody JB, Chenevert TL, Rehemtulla A, and Ross BD (2004). Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 17, 249-259.
9. Kauppinen RA (2002). Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance and proton spectroscopy. NMR Biomed 15, 6-17.
10. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, and Swartz HM (2000). Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2, 152-165.
11. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, et al. (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2, 581-587.
12. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, Ahmed B, Sun X, Ni Y, Bosmans H, Hermans R, et al. (2005). Diffusion-weighted magnetic resonance imaging allows non-invasive in vivo monitoring of the effects of combretastatin A-4 phosphate after repeated administration. Neoplasia 7, 779-787.
13. Moffat BA, Chenevert TL, Meyer CR, Mckeever PE, Hall DE, Hoff BA, Johnsom TD, Rehemtulla A, and Ross BD (2006). The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8, 259-267.
14. Vlaardingerbroek MT and den Boer JA (1999). Magnetic Resonance Imaging, 2nd ed, Springer, New York, pp. 354-360.
15. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, and Gillies RJ (2005). Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478. Neoplasia 7, 475-485.
16. Malet-Martino M and Martino R (2002). Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7, 288-323.
17. Glynne-Jones R, Dunst J, and Sebag-Montefiore D (2005). The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 17, 361-371.
18. 0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol 17, 1103-1110.
19. Machiels J-P, Duck L, Honhon B, Coster B, Coche J-C, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, et al. (2005). Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape Study. Ann Oncol 16, 1898-1905.
20. Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, and Cognetti F (2003). Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14, 1378-1382.
21. Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso EDL, Del Bianco P, Sotti G, Lise G, et al. (2005). A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 16, 1140-1146.
22. Rutten H, Sebag-Montefiore D, Glynne-Jones R, Rullier E, Peeters M, Brown G, Van Cutsem E, Ricci S, Van de Velde CJ, and Quirke P (2006). Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study. J Clin Oncol (Meet Abstr) 24, 3528.
23. Gerard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, and Gilles F (2003). Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with highdose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21, 1119-1124.
24. Minsky BD (2003). Oxaliplatin-based combined-modality therapy for rectal cancer. Semin Oncol 30, 26-33.
25. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, and Ishitsuka H (1999). X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5, 2948-2953.
26. Magne N, Fischel JL, Formento P, Erienne MC, Dubreuil A, Marcie S, Lagrange JL, and Milano G (2003). Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology 64, 280-287.
27. Kjellstrom J, Kjellen E, and Johansson A (2005). In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 44, 687-693.
28. Cividalli A, Ceciarelli F, Lividi E, Altavista P, Cruciani G, Marchetti P, and Danesi DT (2002). Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52, 1092-1098.
29. Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, and Sauer R (2003). Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21, 3098-3104.
30. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, and McDonald AC (2006). A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 17, 50-56.
31. Machiels JPP, Duck L, Honhon B, Coster B, Coche JP, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, et al. (2005). Phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: the RadiOxCape Study. Ann Oncol 16, 1898-1905.
32. Fakih MG, Rajput A, Yang GY, Pendyala L, Toth K, Smith JL, Lawrence DD, and Rustum YM (2006). A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 1, 1462-1470.
33. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, and Allal C (2006). In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 57, 709-718.
34. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, and Ishitsuka H (1998). Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34, 1274-1281.
35. Lyng H, Haraldset O, and Rofstad EK (2000). Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Res Med 43, 828-836.
36. Herneth AM, Guccione S, and Bednarski M (2003). Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 45, 208-213.
37. Evelhoch JL (1999). Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10, 254-259.
38. Gillies RJ, Bhujwalla ZM, Evelhoch J, Garwood M, Neeman M, Robinson SP, Sotak CH, and Van Der Sanden B (2000). Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2 (1-2), 139-151.
39. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, and Laval-Jeantet M (1988). Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168, 497-505.
40. Morvan D (1995). In vivo measurement of diffusion and pseudo-diffusion in skeletal muscle at rest and after exercise. Magn Reson Imaging 13, 193-199.
41. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, and Doran S (2002). Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360, 307-308.
42. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92, 2029-2036.
43. Galons JP, Altbach MI, Paine-Murrieta G, Taylor CW, and Gilles RJ (1999). Early increases in breast tumor xenografts water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1, 113-117.
44. Poptani H, Puumalainen A-M, Gröhn OHJ, Loimas S, Kainulainen R, Ylä-Herttuala S, and Kauppinen RA (1998). Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 5, 101-109.
45. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ, and Stopeck A (2004). Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6, 831-837.
46. Zhou B-BS and Bartek J (2004). Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4, 1-10.